EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Vedolizumab Achieves Pan‐Enteric Mucosal Healing in Crohn's Disease: A Prospective Observational Study

Offir Ukashi iD, Adi Lahat iD, Bella Ungar, Hadar Levy, Adi Talan Asher, Pinhas Eidler, Shomron Ben-Horin iD, Rami Eliakim iD, Uri Kopylov iD

United European Gastroenterology Journal · 2025-12 · 13 (10) · 1974-1983

DOI: 10.1002/ueg2.70103 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 07.09.2025. Verfasst von Offir Ukashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sheba Medical Center Tel Hashomer, Faculty of Medical and Health Sciences, Gastroenterology Institute, Tel-Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal, Humanized, Intestinal Mucosa, Gastrointestinal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medtronic, Takeda Israel Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mucosal healing (MH) is a key treatment goal in Crohn's disease (CD). However, evidence on pan‐enteric MH (PE‐MH) in CD patients treated with vedolizumab remains limited. We aimed to assess vedolizumab efficacy in achieving PE‐MH using PillCam Crohn's capsule.

Methods

This prospective, open‐label observational study included CD patients with intestinal inflammation (SB‐Lewis score [LS] ≥ 220 and/or colonic‐Eliakim score [ES] > 0) who initiated vedolizumab and were followed with C‐reactive protein (CRP), fecal calprotectin (FCP), and PillCam Crohn's capsule at baseline and after 14 and 52 weeks. In cases of exclusive SB involvement, colonic preparation and assessment were omitted. LS and ES were calculated when applicable. The primary outcome was PE‐MH, defined as LS < 135 for SB‐VCE assessment, and ES = 0 for PE‐VCE assessment. Secondary outcomes included SB‐MH (LS < 135), colonic‐MH (ES = 0) and biochemical remission (FCP < 150 μg/g). An exploratory outcome for SB‐MH was defined as a LS < 350, which has previously been shown to predict future flares in CD.

Results

Of the 60 screened patients, 44 were enrolled (median age: 29.0 [22.0–45.5] years; 43.2% male; Ileum [L1]‐54.5%, Colon [L2]‐41.0%, Ileo‐colon [L3]‐4.5%). At week 52, 7/44 (15.9%) patients reached PE‐MH compared to baseline (risk difference [RD] 15.9%, 95% confidence interval [CI] 5.1%–26.7%, p = 0.016). 8/44 (18.2%) and 9/44 (20.5%) patients achieved SB‐MH at week 52 and 14, respectively, compared to 2/44 (4.5%) at baseline. Using the less stringent SB‐MH criterion (LS < 350), rates improved significantly at week 52 versus baseline (45.5% vs. 25.0%, p = 0.049). All study indices decreased during follow‐up (baseline, week 14, week 52): CRP (11.8, 5.8, 5.0: p = 0.152), FCP (758, 418, 158: p = 0.004), LS (900, 225, 225, p < 0.001), and ES (18.0, 4.0, 4.0: p < 0.001). 14/44 (31.8%) patients reached biochemical remission ( p = 0.049) at week 52 compared to 5/44 (11.4%) at baseline.

Conclusion

Vedolizumab treatment led to significant biochemical and endoscopic improvement, including SB‐MH and PE‐MH, through 52 weeks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAntibodies, Monoclonal, HumanizedIntestinal MucosaGastrointestinal AgentsWound HealingHumansMaleFemaleProspective StudiesAdultTreatment OutcomeLeukocyte L1 Antigen ComplexMiddle AgedC-Reactive ProteinYoung AdultFecesRemission InductionCapsule EndoscopyColonSeverity of Illness Index

Stichwörter der Autor:innen

Crohn’s diseaseC‐reactive proteinPillCam Crohn's capsulefecal calprotectinpan‐enteric capsule endoscopypan‐enteric mucosal healingprospective observational studysmall bowel mucosal healingvedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsLeukocyte L1 Antigen ComplexC-Reactive Protein

Autor:innen und Institutionen

  • Sheba Medical Center Tel Hashomer, Faculty of Medical and Health Sciences, Gastroenterology Institute, Tel-Aviv University, Tel Aviv, Israel.
  • Department of Gastroenterology, Assuta Ashdod Hospital, Ashdod, Israel.

ORCID-Profile: Offir Ukashi, Adi Lahat, Shomron Ben-Horin, Rami Eliakim, Uri Kopylov

Förderung

  • Medtronic
  • Takeda Israel Ltd

Zitieren

APA

Ukashi, O., Lahat, A., Ungar, B., Levy, H., Asher, A. T., Eidler, P., Ben-Horin, S., Eliakim, R., & Kopylov, U. (2025). Vedolizumab Achieves Pan‐Enteric Mucosal Healing in Crohn's Disease: A Prospective Observational Study. United European Gastroenterology Journal, 13(10), 1974-1983. https://doi.org/10.1002/ueg2.70103

Vancouver

Ukashi O, Lahat A, Ungar B, Levy H, Asher AT, Eidler P, et al. Vedolizumab Achieves Pan‐Enteric Mucosal Healing in Crohn's Disease: A Prospective Observational Study. United European Gastroenterology Journal. 2025;13(10):1974-1983. doi:10.1002/ueg2.70103

BibTeX
@article{Ukashi2025,
  author = {Ukashi, Offir and Lahat, Adi and Ungar, Bella and Levy, Hadar and Asher, Adi Talan and Eidler, Pinhas and Ben-Horin, Shomron and Eliakim, Rami and Kopylov, Uri},
  title = {Vedolizumab Achieves Pan‐Enteric Mucosal Healing in Crohn's Disease: A Prospective Observational Study},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  volume = {13},
  number = {10},
  pages = {1974--1983},
  doi = {10.1002/ueg2.70103}
}
Kostenlos starten →